These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37381042)

  • 1. Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints.
    Lu J; Ma X; Zhang H; Xiao Z; Li M; Wu J; Ju Z; Chen L; Zheng L; Ge J; Liang X; Bao W; Wu P; Ding D; Yen TC; Guan Y; Zuo C; Zhao Q;
    Transl Neurodegener; 2023 Jun; 12(1):34. PubMed ID: 37381042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition.
    Rauchmann BS; Schneider-Axmann T; Perneczky R;
    J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1289-1295. PubMed ID: 34187867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
    JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline.
    Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q;
    ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
    Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
    ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.
    Dowling NM; Johnson SC; Gleason CE; Jagust WJ;
    Neuroimage; 2015 Jan; 105():357-68. PubMed ID: 25450107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline.
    Bucci M; Chiotis K; Nordberg A;
    Mol Psychiatry; 2021 Oct; 26(10):5888-5898. PubMed ID: 34593971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between biomarkers in aging and dementia.
    Jagust WJ; Landau SM; Shaw LM; Trojanowski JQ; Koeppe RA; Reiman EM; Foster NL; Petersen RC; Weiner MW; Price JC; Mathis CA;
    Neurology; 2009 Oct; 73(15):1193-9. PubMed ID: 19822868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
    Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of
    Lu J; Ju Z; Wang M; Sun X; Jia C; Li L; Bao W; Zhang H; Jiao F; Lin H; Yen TC; Cui R; Lan X; Zhao Q; Guan Y; Zuo C;
    Eur Radiol; 2023 Jul; 33(7):4567-4579. PubMed ID: 37099173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma p-tau231, p-tau181, PET Biomarkers, and Cognitive Change in Older Adults.
    Meyer PF; Ashton NJ; Karikari TK; Strikwerda-Brown C; Köbe T; Gonneaud J; Pichet Binette A; Ozlen H; Yakoub Y; Simrén J; Pannee J; Lantero-Rodriguez J; Labonté A; Baker SL; Schöll M; Vanmechelen E; Breitner JCS; Zetterberg H; Blennow K; Poirier J; Villeneuve S;
    Ann Neurol; 2022 Apr; 91(4):548-560. PubMed ID: 35084051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
    Simrén J; Brum WS; Ashton NJ; Benedet AL; Karikari TK; Kvartsberg H; Sjons E; Lussier FZ; Chamoun M; Stevenson J; Hopewell R; Pallen V; Ye K; Pascoal TA; Zetterberg H; Rosa-Neto P; Blennow K
    Alzheimers Res Ther; 2022 Dec; 14(1):192. PubMed ID: 36544221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Principal-Component Analysis-Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes.
    Blazhenets G; Frings L; Sörensen A; Meyer PT;
    J Nucl Med; 2021 Jun; 62(6):855-860. PubMed ID: 33097630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.